-
An elevated resting heart rate is a risk factor for heart disease.
-
The joint cardiovascular practice guidelines of the American College of Cardiology (ACC) and the American Heart Association (AHA) are largely based on expert opinion, case studies, or "standard of care," rather than on scientific evidence.
-
Ranolazine has gained expanded approval from the FDA for the treatment of chronic angina.
-
The ECG shown above was obtained from a 60-year-old woman who presented with an acute stroke. Is her ECG consistent with this diagnosis, and/or suggestive of something more?
-
In light of an increasing internationally mobile community, the primary care physician may see patients who have recently traveled overseas. This article highlights the manifestations of diseases that, although we may not see them often, can fool us with confusing symptoms.
-
-
Individualization of therapy with pharmacogenetics; the rate vs rhythm debate; the FDA's Risk Evaluation and Mitigation Strategy; FDA actions.
-
-
Since the risk of gastrointestinal bleeding is increased when clopidogrel is added to aspirin therapy in patients with acute coronary syndromes (ACS), many prescribe proton-pump inhibitors (PPIs) to reduce this risk. However, mechanistic studies suggest that PPIs may reduce the effectiveness of clopidogrel.
-
Revascularization, in conjunction with optimal medical therapy, remains a critical component in therapy for patients with obstructive coronary artery disease (CAD).
